Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 10:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 3,201 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: T-Cell Clear all

Conditions: Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma
Interventions: DC/MM Fusion Vaccine, GM-CSF; Biological · Drug
Lead sponsor: David Avigan; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Anaplastic Large-Cell Lymphoma
Interventions: Denileukin Diftitox, Denileukin diftitox, ifosfamide, cyclophosphamide, etoposide; Drug
Lead sponsor: Columbia University; Other
Eligibility: 2 Years to 24 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Lymphoma, B-cell Lymphoma
Interventions: Leukapheresis, Stem Cell Transplant, CD19-specific T Cell Infusion, IL-2, Carmustine, Etoposide, Cytarabine, Melphalan; Procedure · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma, HTLV-1 Infection
Interventions: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Etoposide, Lenalidomide, Multigated Acquisition Scan, Positron Emission Tomography, Prednisone, Vincristine Sulfate; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 19
States / cities: Atlanta, Georgia • City of Saint Peters, Missouri • Creve Coeur, Missouri + 11 more

Conditions: Mycosis Fungoides
Interventions: Mechlorethamine Hydrochloride Gel, Total Skin Electron Beam Radiation Therapy; Drug · Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Refractory Acute Myeloid Leukemia (AML), Relapsed Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, AML (Acute Myeloid Leukemia)
Interventions: CD64 CAR T Cells; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Recurrent Mycosis Fungoides, Refractory Mycosis Fungoides, Stage I Mycosis Fungoides, Stage II Mycosis Fungoides, Stage III Mycosis Fungoides
Interventions: Quality-of-Life Assessment, Objective Grading of Skin Findings; Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2030
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: B Cell Lymphoma, Acute Lymphoblastic Leukemia, Pediatric, Lymphoma
Interventions: Fludarabine, Cyclophosphamide, Autologous CD22 CAR T; Drug
Lead sponsor: Kara Lynn Davis; Other
Eligibility: 1 Year to 30 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Stanford, California

Conditions: X-linked Agammaglobulinemia, XLA, Primary Immune Deficiency, CVID, Common Variable Immunodeficiency, Primary Antibody Deficiencies, Secondary Hypogammaglobulinemia
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 6 Months and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 3
States / cities: St. Petersburg, Florida • Chapel Hill, North Carolina • Durham, North Carolina

Conditions: Leukemia, Acute Lymphoblastic, Lymphoblastic Leukemia, Acute, Childhood
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 3 Years to 25 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Severe Aplastic Anemia
Interventions: Fludarabine, Cyclophosphamide, Total Body Irradiation, Rabbit ATG; Drug · Radiation
Lead sponsor: Northside Hospital, Inc.; Other
Eligibility: 1 Year to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Interventions: Everolimus, Nelarabine, Cyclophosphamide, Etoposide; Drug
Lead sponsor: Emory University; Other
Eligibility: 2 Years to 29 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 4
States / cities: Atlanta, Georgia • New York, New York • Cincinnati, Ohio + 1 more

Conditions: Leukemia
Interventions: autologous tumor cell vaccine, therapeutic autologous dendritic cells, tumor cell-derivative vaccine therapy; Drug · Procedure
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Infections
Interventions: Allogeneic lymphocyte transfer; Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: CD19 Positive, CD22 Positive, Minimal Residual Disease, Progressive Disease, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Non-Hodgkin Lymphoma
Interventions: Autologous CD19/CD22 Chimeric Antigen Receptor T-cells, Cyclophosphamide, Fludarabine; Biological · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 6 Months to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Relapsed or Refractory Lymphoproliferative Malignancies, Hodgkin's Lymphoma, Peripheral T-cell Lymphoma, B-cell Lymphoma, Waldenstrom's Macroglobulinemia
Interventions: Pralatrexate Injection, Gemcitabine Hydrochloride, Vitamin B12, Folic Acid; Drug · Dietary Supplement
Lead sponsor: Acrotech Biopharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 15
States / cities: Los Angeles, California • Stanford, California • Denver, Colorado + 11 more

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Psychosocial Effects of Cancer and Its Treatment
Interventions: psychosocial assessment and care; Procedure
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2017
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Lymphoma, Precancerous/Nonmalignant Condition
Interventions: PEG-interferon alfa-2b, Interferon alfa-2b, Valproic Acid, Zidovudine; Biological · Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Lymphoma, B-Cell, Chronic Lymphocytic Leukemia, Precursor B-Cell Acute Lymphoblastic Leukemia
Interventions: FT819, Cyclophosphamide, Fludarabine, IL-2, Bendamustine; Drug
Lead sponsor: Fate Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2039
U.S. locations: 18
States / cities: Birmingham, Alabama • Phoenix, Arizona • Davis, California + 15 more

Conditions: Metastatic Breast Cancer, Triple Negative Breast Cancer
Interventions: cMet RNA CAR T cells; Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Large-cell Lymphoma
Interventions: Rapcabtagene autoleucel (YTB323); Biological
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma, Refractory Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
Interventions: Anti-GPC3-CAR Autologous T Lymphocytes, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Echocardiography Test, Fludarabine, Leukapheresis, Magnetic Resonance Imaging, Multigated Acquisition Scan; Biological · Procedure · Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Sporadic, Inclusion Body, Myositis
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 25 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 2
States / cities: Bethesda, Maryland • Philadelphia, Pennsylvania

Conditions: Recurrent Malignant Glioma, Recurrent WHO Grade 3 Glioma, Recurrent WHO Grade 4 Glioma, WHO Grade 2 Glioma, WHO Grade 3 Glioma, WHO Grade 4 Glioma
Interventions: Anti-GARP Chimeric Antigen Receptor-T Cells, Biospecimen Collection, Chest Radiography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pheresis, Surgical Procedure; Biological · Procedure
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Search by objective public record fields.

DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM

Denileukine Diftitox for Relapsed ALCL

CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

Low Dose Total Skin Electron Beam Radiation Therapy and Mechlorethamine Hydrochloride Gel in Treating Patients With Mycosis Fungoides

CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML

Low-Dose Total Skin Electron Therapy in Treating Patients With Refractory or Relapsed Stage IB-IIIA Mycosis Fungoides

CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies

COVID-19 Vaccine Responses in PIDD Subjects

CAR-Multicenter Analysis (CAR-MA): Retrospective Study to Characterize CAR T-cell Outcomes and Related Toxicities in Children and Young Adults With B-ALL

Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia

Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/Lymphoma

Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia

A Pilot Study of Allogeneic Lymphocyte Transfer in HIV Infection

Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma

Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies

Caregiver Support in the Coping of Patients Who Are Undergoing a Donor Bone Marrow Transplant

Zidovudine, Interferon Alfa-2b, PEG-Interferon Alfa-2b in Patients With HTLV-I Associated Adult T-Cell Leukemia/Lymphoma

FT819 in Subjects With B-cell Malignancies

cMet CAR RNA T Cells Targeting Breast Cancer

CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study)

Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma

Immune Abnormalities in Sporadic Inclusion Body Myositis

Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas